MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia

Leukemia

Volumn 28, Issue 4, 2014, Pages 804-812

  Diaz Beya M ^a,b   Brunet, S ^b,c   Nomdedeu J ^b,c   Tejero, R ^a   Diaz T ^a   Pratcorona, M ^a,b   Tormo, M ^d   Ribera, J M ^e   Escoda, L ^f   Duarte, R ^g   Gallardo, D ^h   Heras, I ⁱ   Queipo De Llano, M P ^j   Bargay, J ^k   Monzo, M ^c   Sierra, J ^b,c   Navarro, A ^a   Esteve, J ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^g HOSPITAL DURAN I REYNALS   (Spain)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ HOSPITAL MORALES MESEGUER   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^k HOSPITAL SON LLÀTZER   (Spain)

more..

Author keywords

AML; miR 135a; miR 196b; miR 409 3p; miR 644; miRNA

Indexed keywords

CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MICRORNA; MICRORNA 135A; MICRORNA 196B; MICRORNA 200C; MICRORNA 23A; MICRORNA 23B; MICRORNA 409 3P; MICRORNA 627; MICRORNA 644; MITOXANTRONE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; CONFERENCE PAPER; CYTOGENETICS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; INTERMEDIATE RISK CYTOGENETIC ACUTE MYELOID LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RISK;

EID: 84898446853     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.281     Document Type: Conference Paper

References (53)

1. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-2972.
2. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
4. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)
5. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010; 10: 23-36.
6. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411-6418.
7. Schotte D, Pieters R, Den Boer M. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2011; 26: 1-12.
8. Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008; 3: e2141.
9. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111: 5078-5085.
10. Diaz-Beya M, Navarro A, Ferrer G, Diaz T, Gel B, Camos M et al. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia 2012; 27: 595-603.
11. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-1129.
12. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945-3950. (Pubitemid 351723504)
13. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928. (Pubitemid 351620112)
14. Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26: 5078-5087.
15. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
16. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
17. Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 2012; 3: 688.
18. Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, Lowenberg B et al. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia 2012; 27: 100-106.
19. Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 5257-5264.
20. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 120: 249-258.
21. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008; 15: 352-358.
22. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010; 84: 1-16.
23. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. (Pubitemid 40839735)
24. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866. (Pubitemid 44629897)
25. Agirre X, Mart́nez-Climent JÁ , Odero M, Pró sper F. Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 2011; 26: 395-403.
26. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26: 2011-2018.
27. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
28. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618-3620. (Pubitemid 41609201)
29. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633. (Pubitemid 41095065)
30. Navarro A, Marrades RM, Vinolas N, Quera A, Agusti C, Huerta A et al. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009; 76: 162-169.
31. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007; 3: 11-17. (Pubitemid 47075796)
32. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
34. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2012; 48: 452-458.
35. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
36. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
37. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
38. Rücker F, Russ A, Cocciardi S, Kett H, Schlenk R, Botzenhardt U et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia 2012; 27: 353-361.
39. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009; 113: 3314-3322.
40. Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, de Haas V, Trka J et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer 2012; 58: 715-721.
41. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 2012; doi:10.1007/s00345-012-1010-2.
42. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009; 114: 2945-2951.
43. Wu S, Lin Y, Xu D, Chen J, Shu M, Zhou Y et al. MiR-135a functions as a selective killer of malignant glioma. Oncogene 2012; 31: 3866-3874.
44. Yamada Y, Hidaka H, Seki N, Yoshino H, Yamasaki T, Itesako T et al. Tumorsuppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci 2012; 104: 304-312.
45. Nagel R, Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-5802.
46. Liu S, Guo W, Shi J, Li N, Yu X, Xue J et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2012; 56: 389-396.
47. Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y et al. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer 2012; 12: 111.
48. Zhou W, Li X, Liu F, Xiao Z, He M, Shen S et al. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim Biophys Sin 2012; 44: 838-846.
49. Li C, Nie H, Wang M, Su L, Li J, Yu B et al. MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett 2012; 320: 189-197.
50. Weng C, Dong H, Chen G, Zhai Y, Bai R, Hu H et al. miR-409-3p inhibits HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin. Cancer Lett 2012; 323: 171-179.
51. Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 2011; 129: 2600-2610.
52. Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC et al. Characterization of the melanoma miRNAome by deep sequencing. PLoS One 2010; 5: e9685.
53. Schotte D, Akbari Moqadam F, Lange-Turenhout EA, Chen C, van Ijcken WF, Pieters R et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 2011; 25: 1389-1399.